The risk of congenital malformations associated with exposure to β-blockers early in pregnancy: A meta-analysis

Hypertension

Volumn 62, Issue 2, 2013, Pages 375-381

  Yakoob, Mohammad Y ^a   Bateman, Brian T ^b,c   Ho, Eugenia ^d   Hernandez Diaz, Sonia ^a   Franklin, Jessica M ^c   Goodman, Julie E ^a   Hoban, Rebecca A ^e  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

blockers; Cleft lip palate; Congenital; Congenital anomalies; Heart defects; Neural tube defects; Pregnancy; Trimester, first

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; METOPROLOL; OXPRENOLOL; PINDOLOL; PROPRANOLOL;

ARTICLE; CARDIOVASCULAR MALFORMATION; CLEFT LIP PALATE; CONGENITAL MALFORMATION; DRUG INDUCED DISEASE; FIRST TRIMESTER PREGNANCY; HUMAN; HYPOSPADIAS; NEURAL TUBE DEFECT; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TERATOGENICITY;

Β-BLOCKERS; CLEFT LIP/PALATE; CONGENITAL ANOMALIES; HEART DEFECTS, CONGENITAL; NEURAL TUBE DEFECTS; PREGNANCY; TRIMESTER, FIRST;

ABNORMALITIES, DRUG-INDUCED; ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; CLEFT PALATE; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; NEURAL TUBE DEFECTS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; RISK;

EID: 84880935908     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.00833     Document Type: Article

References (30)

1. Andrade SE, Raebel MA, Brown J, Lane K, Livingston J, Boudreau D, Rolnick SJ, Roblin D, Smith DH, Dal Pan GJ, Scott PE, Platt R. Outpatient use of cardiovascular drugs during pregnancy. Pharmacoepidemiol Drug Saf. 2008;17:240-247.
2. Bateman BT, Hernandez-Diaz S, Huybrechts KF, Palmsten K, Mogun H, Ecker JL, Fischer MA. Patterns of outpatient antihypertensive medication use during pregnancy in a Medicaid population. Hypertension. 2012;60:913-920.
3. Centers for Disease Control and Prevention (CDC). Update on overall prevalence of major birth defects-Atlanta, Georgia, 1978-2005. MMWR Morb Mortal Wkly Rep. 2008;57:1-5.
4. Miniño AM, Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2008. Natl Vital Stat Rep. 2011;59:1-126.
5. Podymow T, August P. Update on the use of antihypertensive drugs in pregnancy. Hypertension. 2008;51:960-969.
6. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008-2012.
7. Senn SJ. Overstating the evidence: double counting in meta-analysis and related problems. BMC Med Res Methodol. 2009;9:10.
8. Puhó EH, Szunyogh M, Métneki J, Czeizel AE. Drug treatment during pregnancy and isolated orofacial clefts in Hungary. Cleft Palate Craniofac J. 2007;44:194-202.
9. Medveczky E, Puhó E, Czeizel EA. The use of drugs in mothers of offspring with neural-tube defects. Pharmacoepidemiol Drug Saf. 2004;13:443-455.
10. Cafri G, Kromrey JD, Brannick MT. A SAS macro for statistical power calculations in meta-analysis. Behav Res Methods. 2009;41:35-46.
11. Bánhidy F, Acs N, Puhó EH, Czeizel AE. Chronic hypertension with related drug treatment of pregnant women and congenital abnormalities in their offspring: a population-based study. Hypertens Res. 2011;34:257-263.
12. Caton AR, Bell EM, Druschel CM, Werler MM, Lin AE, Browne ML, McNutt LA, Romitti PA, Mitchell AA, Olney RS, Correa A; National Birth Defects Prevention Study. Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations. Hypertension. 2009;54:63-70.
13. Caton AR, Bell EM, Druschel CM, Werler MM, Mitchell AA, Browne ML, McNutt LA, Romitti PA, Olney RS, Correa A; National Birth Defects Prevention Study. Maternal hypertension, antihypertensive medication use, and the risk of severe hypospadias. Birth Defects Res A Clin Mol Teratol. 2008;82:34-40.
14. Cedergren MI, Selbing AJ, Källén BA. Risk factors for cardiovascular malformation-a study based on prospectively collected data. Scand J Work Environ Health. 2002;28:12-17.
15. Nakhai-Pour HR, Rey E, Berard A. Antihypertensive medication use during pregnancy and the risk of major congenital malformations or small-for- gestational-age newborns. Pharmacoepidemiol Drug Saf. 2009;18:S76.
16. Nakhai-Pour HR, Rey E, Berard A. Antihypertensive medication use during pregnancy and the risk of major congenital malformations or smallfor- gestational-age newborns. Birth Defects Res A Clin Mol Teratol. 2009;85:416.
17. Nakhai-Pour HR, Rey E, Bérard A. Antihypertensive medication use during pregnancy and the risk of major congenital malformations or smallfor-gestational-age newborns. Birth Defects Res B Dev Reprod Toxicol. 2010;89:147-154.
18. Queisser-Luft A, Eggers I, Stolz G, Kieninger-Baum D, Schlaefer K. Serial examination of 20,248 newborn fetuses and infants: correlations between drug exposure and major malformations. Am J Med. Genet. 1996;63:268-276.
19. Sípek A, Gregor V, Velebil P, Horácek J, Masátová D, Světnicová K. Incidence of congenital defects in the children of mothers who used medications in the first trimester of pregnancy in the Czech Republic 1996- 2001. Ceska Gynekol. 2003;68:401-419.
20. Davis RL, Eastman D, McPhillips H, Raebel MA, Andrade SE, Smith D, Yood MU, Dublin S, Platt R. Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. Pharmacoepidemiol Drug Saf. 2011;20:138-145.
21. Källén BA, Otterblad Olausson P. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol. 2003;17:255-261.
22. Erić M, Leppée M, Culig J, Krivokuća D. Pregnancy and drugs for cardiovascular diseases. Acta Cardiol. 2009;64:23-28.
23. Lennestål R, Otterblad Olausson P, Källén B. Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. Eur J Clin Pharmacol. 2009;65:615-625.
24. Aberg A, Westbom L, Källén B. Congenital malformations among infants whose mothers had gestational diabetes or preexisting diabetes. Early Hum Dev. 2001;61:85-95.
25. Jensen DM, Damm P, Moelsted-Pedersen L, Ovesen P, Westergaard JG, Moeller M, Beck-Nielsen H. Outcomes in type 1 diabetic pregnancies: a nationwide, population-based study. Diabetes Care. 2004;27:2819-2823.
26. Kitzmiller JL, Wallerstein R, Correa A, Kwan S. Preconception care for women with diabetes and prevention of major congenital malformations. Birth Defects Res A Clin Mol Teratol. 2010;88:791-803.
27. Ray JG, O'Brien TE, Chan WS. Preconception care and the risk of congenital anomalies in the offspring of women with diabetes mellitus: a meta-analysis. QJM. 2001;94:435-444.
28. Yang J, Cummings EA, O'connell C, Jangaard K. Fetal and neonatal outcomes of diabetic pregnancies. Obstet Gynecol. 2006;108(3 pt 1):644-650.
29. Levit RD, Reynolds HR, Hochman JS. Cardiovascular disease in young women: a population at risk. Cardiol Rev. 2011;19:60-65.
30. Li DK, Yang C, Andrade S, Tavares V, Ferber JR. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study. BMJ. 2011;343:d5931.